Blood Medicine

Blowing the Whistle on One of the Deadliest Prescription Drugs Ever

Business & Finance, Business Reference, Corporate History, Biography & Memoir, Business, Industries & Professions, Industries
Cover of the book Blood Medicine by Kathleen Sharp, Penguin Publishing Group
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Kathleen Sharp ISBN: 9781101617137
Publisher: Penguin Publishing Group Publication: August 28, 2012
Imprint: Plume Language: English
Author: Kathleen Sharp
ISBN: 9781101617137
Publisher: Penguin Publishing Group
Publication: August 28, 2012
Imprint: Plume
Language: English

Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years.” — John Lescroart, New York Times bestselling author of Damage

Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue—and still does.  In 2012, world famous cyclist, Olympian, and Tour de France champion Lance Armstrong was banned from professional cycling on doping charges for using EPO (the blanket name for the drugs Procrit and Epogen), resulting in a global controversy about abuse, big pharmaceutical companies, and the lies and inaccuracies concerning performance-enhancing drugs.

Mark Duxbury was a J&J salesman who once believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J’s business practices. He was fired and filed a whistleblower suit to warn the public.

When Jan Schlichtman (A Civil Action) learned of Duxbury’s crusade, he signed on. Now, he’s fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Blood Feud rivals A Civil Action for best non-fiction book of the past twenty years.” — John Lescroart, New York Times bestselling author of Damage

Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue—and still does.  In 2012, world famous cyclist, Olympian, and Tour de France champion Lance Armstrong was banned from professional cycling on doping charges for using EPO (the blanket name for the drugs Procrit and Epogen), resulting in a global controversy about abuse, big pharmaceutical companies, and the lies and inaccuracies concerning performance-enhancing drugs.

Mark Duxbury was a J&J salesman who once believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J’s business practices. He was fired and filed a whistleblower suit to warn the public.

When Jan Schlichtman (A Civil Action) learned of Duxbury’s crusade, he signed on. Now, he’s fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.

More books from Penguin Publishing Group

Cover of the book Going Solo by Kathleen Sharp
Cover of the book Power Play by Kathleen Sharp
Cover of the book Stars in Your Eyes by Kathleen Sharp
Cover of the book Herald of Death by Kathleen Sharp
Cover of the book Someone to Remember by Kathleen Sharp
Cover of the book Lorena Garcia's New Taco Classics by Kathleen Sharp
Cover of the book Spy's Honor by Kathleen Sharp
Cover of the book Gilt Trip by Kathleen Sharp
Cover of the book Longarm 270: Longarm and the Lady Bandit by Kathleen Sharp
Cover of the book Veiled Enchantments by Kathleen Sharp
Cover of the book All My Sons by Kathleen Sharp
Cover of the book Can't Buy Me Like by Kathleen Sharp
Cover of the book Trailsman # 260: Blood Wedding by Kathleen Sharp
Cover of the book Home for a Spell by Kathleen Sharp
Cover of the book Saint Therese of Lisieux by Kathleen Sharp
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy